The Abramson Cancer Center (ACC) of the University of Pennsylvania was founded in 1973 and was one of the first Comprehensive Cancer Centers designated by the National Cancer Institute (NCI). Since its inception, the ACC has been continuously funded through the NCI CCSG. The ACC is a matrix center that facilitates transdisciplinary cancer research, education, and patient care. Its 318 members are drawn from 37 Departments and 8 Schools of the University and have $168,806,933 in research and training funding (annual direct costs), a 40% increase since 2004. Of these funds, $156,713,965 is peer-reviewed and $51,462,763 is NCI funded, this funding includes 16 NIH P01s, 5 P50s, 3 P30s, and 1 P20. Commensurate with the growth in funding, the ACC has more than doubled its assigned space since 2004 with the opening of the Perelman Center for Advanced Medicine, the Roberts Proton Therapy Facility, and the Fisher and Colket Translational Research Buildings. Through the development of integrated programs of laboratory, clinical, and population-based research, the ACC seeks to foster pioneering scientific discoveries that can be translated into new methods for cancer prevention, detection, and treatment. Currently, there are 11 multidisciplinary research programs in the ACC: Immunobiology, Tumor Biology, Tumor Virology, Cancer Therapeutics, Pediatric Oncology, Radiobiology and Imaging, Melanoma and Cutaneous Malignancies, Hematologic Malignancies, Breast Cancer, Tobacco and Environmental Carcinogenesis, and Cancer Control. The Cancer Center supports 13 Shared Resources, of which 2 are new and 2 have been restructured. The continuous development of strong Research Programs and leading-edge Shared Resources, the recruitment of outstanding faculty, and the acquisition of additional research space allow the ACC to support the research activities of its members. An ongoing strategic planning/implementation process allows the ACC to identify emerging cancer research areas for future development, while guiding current activities and resource allocations. The ACC supports a wide range of seminars and retreats and promotes interdisciplinary use of research space to facilitate interaction and collaboration among its members. Developmental funds remain critical for the support of faculty recruitment and the funding of innovative pilot projects with the potential for peer-reviewed funding and translation. The ACC has an engaged leadership focused on supporting the transdisciplinary cancer research of its productive membership.

Public Health Relevance

The mission of the Abramson Cancer Center is to reduce the burden of cancer for our patients. Through the development of interactive programs for transdisciplinary cancer research, the ACC strives to translate research discoveries into clinical practice. Advances are disseminated through community outreach and educational programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016520-38S1
Application #
8789009
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-01-15
Project End
2015-11-30
Budget Start
2014-03-18
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$67,498
Indirect Cost
$25,312
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications